These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1115054)

  • 41. Drug metabolism in malnourished children: a study with antipyrine.
    Homeida M; Karrar ZA; Roberts CJ
    Arch Dis Child; 1979 Apr; 54(4):299-302. PubMed ID: 110271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered elimination of antipyrine in patients with acute viral hepatitis.
    Burnett DA; Barak AJ; Tuma DJ; Sorrell MF
    Gut; 1976 May; 17(5):341-4. PubMed ID: 1278717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.
    Miguet JP; Vuitton D; Deschamps JP; Allemand H; Joanne C; Bechtel P; Carayon P
    Dig Dis Sci; 1981 Aug; 26(8):718-22. PubMed ID: 7261836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1977 Apr; 21(4):470-81. PubMed ID: 849678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of short-term water deprivation on antipyrine disposition.
    Prasad P; Jung D; Niazi S
    J Pharm Sci; 1985 Mar; 74(3):338-9. PubMed ID: 4009446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases.
    el-Yazigi A; Raines DA; Wahab FA; Sieck JO; Ernst P; Ali H; Dossing M
    J Clin Pharmacol; 1995 Jun; 35(6):615-21. PubMed ID: 7665722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impairment of hepatic drug metabolism in alcoholics.
    Harman AW; Frewin DB; Priestly BG; Alexander CB
    Br J Clin Pharmacol; 1979 Jan; 7(1):45-8. PubMed ID: 760741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers.
    Bartoli A; Gatti G; Cipolla G; Barzaghi N; Veliz G; Fattore C; Mumford J; Perucca E
    Epilepsia; 1997 Jun; 38(6):702-7. PubMed ID: 9186253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of fenfluramine on disposition and rate of antipyrine elimination.
    O'Malley K; Stevenson IH; West M
    Pharmacology; 1975; 13(1):12-9. PubMed ID: 1153500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of antipyrine in epileptic patients.
    Rimmer EM; Routledge PA; Tsanaclis LM; Richens A
    Br J Clin Pharmacol; 1986 May; 21(5):511-4. PubMed ID: 3718808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs.
    Vesell ES; Lee CJ; Passananti GT; Shively CA
    Pharmacology; 1973; 10(6):317-28. PubMed ID: 4150321
    [No Abstract]   [Full Text] [Related]  

  • 53. Antipyrine clearance in congenital adrenal hyperplasia.
    Loche S; Rifkind AB; Stoner E; Conney AH; New MI
    Clin Endocrinol (Oxf); 1986 Sep; 25(3):233-9. PubMed ID: 3791665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiopyrine half-life as a measure of hepatic enzyme induction: clinical applications in a chronic epileptic population.
    Byrne E; Harman AW; Frewin DB; Hallpike JF
    Clin Exp Neurol; 1979; 16():183-9. PubMed ID: 550940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impairment of antipyrine clearance in humans by propranolol.
    Greenblatt DJ; Franke K; Huffman DH
    Circulation; 1978 Jun; 57(6):1161-64. PubMed ID: 639239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Br Med J; 1977 May; 1(6073):1384-7. PubMed ID: 861646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of phenobarbital on biliary lipid metabolism and hepatic microsomal drug metabolism in patients with cholesterol cholelithiasis.
    Hepner GW
    Am J Dig Dis; 1976 May; 21(6):370-5. PubMed ID: 937312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.
    Buters JT; Zysset T; Reichen J
    Biochem Pharmacol; 1993 Sep; 46(6):983-91. PubMed ID: 8216358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Study of liver function by antipyrine clearance].
    Chrétien P; Boismare F
    LARC Med; 1983; 3(7):504-7. PubMed ID: 6645741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.